Header Logo

Connection

Caroline Tiemessen to Anti-HIV Agents

This is a "connection" page, showing publications Caroline Tiemessen has written about Anti-HIV Agents.
Connection Strength

2,546
  1. Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection. Curr Opin HIV AIDS. 2025 May 01; 20(3):249-256.
    View in: PubMed
    Score: 0,517
  2. Predictors of Cell-Associated Human Immunodeficiency Virus (HIV)-1 DNA Over 1 Year in Very Early Treated Infants. Clin Infect Dis. 2022 03 23; 74(6):1047-1054.
    View in: PubMed
    Score: 0,420
  3. A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. Nat Commun. 2019 01 24; 10(1):412.
    View in: PubMed
    Score: 0,337
  4. Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1-infected children. PLoS One. 2018; 13(4):e0195514.
    View in: PubMed
    Score: 0,320
  5. Single-dose nevirapine exposure affects T cell response and cytokine levels in HIV type 1-infected women. AIDS Res Hum Retroviruses. 2009 Oct; 25(10):1049-53.
    View in: PubMed
    Score: 0,177
  6. African infants' CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine. AIDS. 2007 Aug 20; 21(13):1753-61.
    View in: PubMed
    Score: 0,153
  7. Healthy dynamics of CD4 T cells may drive HIV resurgence in perinatally-infected infants on antiretroviral therapy. PLoS Pathog. 2022 08; 18(8):e1010751.
    View in: PubMed
    Score: 0,108
  8. Reduced HIV-stimulated T-helper cell reactivity in cord blood with short-course antiretroviral treatment for prevention of maternal-infant transmission. Clin Exp Immunol. 2001 Mar; 123(3):443-50.
    View in: PubMed
    Score: 0,098
  9. Quantifying the Dynamics of HIV Decline in Perinatally Infected Neonates on Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2020 10 01; 85(2):209-218.
    View in: PubMed
    Score: 0,095
  10. HIV diagnostic challenges in breast-fed infants of mothers on antiretroviral therapy. AIDS. 2019 09 01; 33(11):1751-1756.
    View in: PubMed
    Score: 0,088
  11. Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible? Virol J. 2016 10 12; 13(1):170.
    View in: PubMed
    Score: 0,072
  12. Influence of intragenic CCL3 haplotypes and CCL3L copy number in HIV-1 infection in a sub-Saharan African population. Genes Immun. 2013 Jan; 14(1):42-51.
    View in: PubMed
    Score: 0,055
  13. In vivo effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1-seropositive mothers. J Acquir Immune Defic Syndr. 2006 Aug 15; 42(5):545-53.
    View in: PubMed
    Score: 0,036
  14. Performance of an in-house multiplex PCR assay for HIV-1 drug resistance testing - A cheaper alternative. J Virol Methods. 2024 Dec; 330:115034.
    View in: PubMed
    Score: 0,031
  15. Growth Trajectories Over the First Year of Life Among Early-Treated Infants with Human Immunodeficiency Virus and Infants Who are Human Immunodeficiency Virus-Exposed Uninfected. J Pediatr. 2024 Jul; 270:114018.
    View in: PubMed
    Score: 0,030
  16. Viral genetic determinants of nonprogressive HIV type 1 subtype C infection in antiretroviral drug-naive children. AIDS Res Hum Retroviruses. 2009 Nov; 25(11):1141-8.
    View in: PubMed
    Score: 0,011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.